Clinical Trials /

Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma

NCT03034135

Description:

This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.

Related Conditions:
  • Glioblastoma
Recruiting Status:

Completed

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
  • Official Title: A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma

Clinical Trial IDs

  • ORG STUDY ID: CAN-201
  • NCT ID: NCT03034135

Conditions

  • Recurrent Glioblastoma

Interventions

DrugSynonymsArms
Disulfiram/CopperDSF-Cu

Purpose

This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM. Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months. Patients will be evaluated for response every 8 weeks. Patients will be followed up 2 years after the last dose of DSF-Cu.

Trial Arms

NameTypeDescriptionInterventions
DSF-CuExperimentalDisulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
  • Disulfiram/Copper

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed GBM (WHO grade IV).

          -  The subject must have completed RT with concurrent TMZ at least 12 weeks prior to the
             planned start of treatment on this study UNLESS there is pathological verification of
             recurrent tumor and at least 4 weeks have elapsed since the end of RT with concurrent
             TMZ.

          -  Experienced first unequivocal progression of tumor by magnetic resonance imaging (MRI)
             [as assessed via Radiologic Assessment in Neuro-Oncology (RANO) criteria within 3
             months from the last dose of TMZ.

          -  Karnofsky performance status (KPS) of at least 60%.

          -  Willing to remain abstinent from consuming alcohol.

          -  Recovered from the toxic effects of prior therapy to < grade 2 toxicity per NCI CTCAE
             prior to study registration (except lymphopenia).

          -  Meets laboratory criteria for the following parameters: ANC, platelets, hemoglobin,
             total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine
             aminotransferase, BUN and creatinine.

          -  11. Females of childbearing potential must be willing to use an acceptable method of
             birth control (i.e., intra-uterine device, diaphragm with spermicide, condom with
             spermicide, or abstinence) for the duration of the study.

        Exclusion Criteria:

          -  Radiographic evidence of leptomeningeal dissemination, gliomatosis cerebri,
             infratentorial tumor, or disease at sites remote from the supratentorial brain.

          -  Enrolled in another clinical trial testing a novel therapy or drug within the past 4
             weeks.

          -  Received more than one course of radiation therapy or more than a total dose of 75 Gy.

          -  History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.

          -  Treatment with the following medications are contraindicated with DSF: metronidazole,
             isoniazid, dronabinol, carbocisteine, lopinavir, paraldehyde, ritonavir, sertraline,
             tindazole, tizanidine, atazanavir.

          -  Fever within 3 days prior to study enrollment.

          -  Active or severe hepatic or renal disease.

          -  Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE

          -  History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to
             glioblastoma, corticosteroid, or anti-epileptic medications.

          -  History of Wilson's disease.

          -  History of hemochromatosis.

          -  Pregnant or breastfeeding.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Objective Response Rate
Time Frame:6 months
Safety Issue:
Description:The percentage of patients with Complete Response or Partial Response according to the RANO criteria.

Secondary Outcome Measures

Measure:Progression Free Survival
Time Frame:6 months
Safety Issue:
Description:Proportion of patients that are free from progressive disease
Measure:Overall Survival
Time Frame:2 years
Safety Issue:
Description:Proportion of patients that are alive
Measure:Toxicity
Time Frame:6 months
Safety Issue:
Description:Adverse events

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Cantex Pharmaceuticals

Last Updated

October 17, 2017